Fiche publication
Date publication
février 2022
Journal
Molecular diagnosis & therapy
Auteurs
Membres identifiés du Cancéropôle Est :
Dr OUDART Jean-Baptiste
,
Pr LEBRE Anne-Sophie
Tous les auteurs :
Beaudoux O, Oudart JB, Riffaud L, Visseaux L, Marchal A, Lebre AS, Grange F
Lien Pubmed
Résumé
Primary mucosal melanomas (PMMs) are rare and clinically heterogeneous, including head and neck (HNMs), vulvovaginal (VVMs), conjunctival (CjMs), anorectal (ARMs) and penile (PMs) melanomas. While the prognosis of advanced cutaneous melanoma has noticeably improved using treatments with immune checkpoint inhibitors (ICIs) and molecules targeting BRAF and MEK, few advances have been made for PMMs because of their poorer response to ICIs and their different genetic profile. This prompted us to conduct a systematic review of molecular studies of PMMs to clarify their pathogenesis and potential therapeutic targets.
Référence
Mol Diagn Ther. 2022 Feb 23;:
